Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK joins the scheme as a Drug Discovery and Development Expert

Andy Pearce

The Business Development Team for the Medical Sciences Division has announced the appointment of a new  expert to its Industry Experts in Residence Scheme. Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK, joined the scheme in October. 

In his role Dr Pearce leads drug discovery projects from target validation through hit-finding and to the delivery of high quality clinical candidates, across broad disease areas, in collaboration with world-leading academic partners. He is a biochemist and cell biologist by training, and received his undergraduate degree and DPhil from the University of Oxford before undertaking postdoctoral studies at the University of Birmingham. Dr Pearce is a Fellow of the Royal Society of Biology, and he occasionally lectures at Oxford and Cambridge Universities and participates in career panels and workshops for scientists.

Dr Pearce said: ‘I am really excited to be taking up the position of Expert in Residence in Drug Discovery and Development. I am looking forward to meeting Oxford colleagues, discussing some of their great science, and contributing whatever I can to help advance Translational Research in Oxford towards medicines to benefit patients’.

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars given by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Pearce has made his expertise in Drug Discovery and Development available to researchers. Dr Pearce will sit in the Target Discovery Institute (TDI), Nuffield Department of Medicine, NDM Research Building on various dates during 2018/19. If you would like to arrange a meeting please contact charlotte.bell@medsci.ox.ac.uk

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.

'Find out more about the scheme and book an appointment with an expert 

Similar stories

Oxford joins consortium to advance quantum drug discovery with £6.8M grant from Innovate UK

Oxford University today joins a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA.

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Immunology and AI drug discovery partnership agreed with Sensyne Health

The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.